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STUDY PROTOCOL Open Access
Immune Function and Muscle Adaptations to
Resistance exercise in Older Adults: Study
Protocol for a Randomized Controlled Trial of a
Nutritional Supplement
Richard A Dennis1,2*, Usha Ponnappan3, Ralph L Kodell4, Kimberly K Garner1,2, Christopher M Parkes1,
Melinda M Bopp1, Kalpana P Padala1,2, Charlotte A Peterson5, Prasad R Padala1,2,6 and Dennis H Sullivan1,2
Abstract
Background: Immune function may influence the ability of older adults to maintain or improve muscle mass,
strength, and function during aging. Thus, nutritional supplementation that supports the immune system could
complement resistance exercise as an intervention for age-associated muscle loss. The current study will determine
the relationship between immune function and exercise training outcomes for older adults who consume a nutritional
supplement or placebo during resistance training and post-training follow-up. The supplement was chosen due
to evidence suggesting its ingredients [arginine (Arg), glutamine (Gln), and β-hydroxy β-methylbutyrate (HMB)]
can improve immune function, promote muscle growth, and counteract muscle loss.
Methods/design: Veterans (age 60 to 80 yrs, N = 50) of the United States military will participate in a randomized
double-blind placebo-controlled trial of consumption of a nutritional supplement or placebo during completion
of three study objectives: 1) determine if 2 weeks of supplementation improve immune function measured as the
response to vaccination and systemic and cellular responses to acute resistance exercise; 2) determine if supplementation
during 36 sessions of resistance training boosts gains in muscle size, strength, and function; and 3) determine if continued
supplementation for 26 weeks post-training promotes retention of training-induced gains in muscle size, strength, and
function. Analyses of the results for these objectives will determine the relationship between immune function and the
training outcomes. Participants will undergo nine blood draws and five muscle (vastus lateralis) biopsies so that the effects
of the supplement on immune function and the systemic and cellular responses to exercise can be measured.
Discussion: Exercise has known effects on immune function. However, the study will attempt to modulate immune
function using a nutritional supplement and determine the effects on training outcomes. The study will also examine
post-training benefit retention, an important issue for older adults, usually omitted from exercise studies. The study will
potentially advance our understanding of the mechanisms of muscle gain and loss in older adults, but more importantly,
a nutritional intervention will be evaluated as a complement to exercise for supporting muscle health during aging.
Trial Registration: Clinicaltrials.gov identifier: NCT02261961, registration date 10 June 2014, recruitment active.
Keywords: sarcopenia, skeletal muscle, aging, immune function, TDAP vaccination, resistance exercise, inflammation,
growth factors, EAS Muscle Armor, Juven
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Background
Effective strategies for rehabilitation are critical to the
health of older adults since age-associated muscle loss
decreases functional ability and increases risk for falls
and fractures, disability, and mortality [1,2]. Resistance
exercise training can be an effective intervention for im-
proving muscle mass, strength, and function in older
adults, but the magnitude of benefit varies considerably
among individuals [3,4]. This suggests that older adults
with less adaptive potential will have greater muscle loss
due to aging and that their rehabilitation will be less ef-
fective. Thus, a better understanding of the effects of
aging on the cellular and biochemical mechanisms con-
trolling muscle health may be needed to design interven-
tions (for example, nutritional supplementation) that
complement resistance training. Specifically, this protocol
will determine whether immune function influences
muscle adaptation to resistance exercise and whether the
influence is affected by a nutritional supplement (Arg,
Gln, and HMB), whose ingredients appear capable of im-
proving immune function, promoting muscle growth, and
counteracting muscle loss [5]. A randomized controlled
trial is being conducted in which older adults consume a
nutritional supplement or placebo during a resistance
training program and post-training period in order to
determine if the supplement improves immune func-
tion, boosts muscle adaptation to training, and supports
post-training retention of the exercise-derived benefits
(Figure 1).
The bodily systems are often co-dependent during
health and dysfunction, but the role of immune function
in maintaining or improving muscle health for older
adults is unknown. The study will investigate the effects
of nutritional supplementation on variables for humoral,
innate, and adaptive immune functions and determine
their relationship to exercise training outcomes. With
aging, the antibody response to vaccination is weaker
and wanes sooner over time, meaning that older adults
may not possess protective antibody titers [6]. T-cells
and monocytes have a diminished ability to proliferate
and CD4+ helper t-cells, the CD8+ suppressor t-cells,
and other t-cell subsets become imbalanced [7]. These
changes increase susceptibility to infectious disease but
may also indicate that other systemic problems exist that
may specifically affect muscle. Acute increases in plasma
pro- and anti-inflammatory cytokines after acute exercise
are thought to initiate muscle repair of damage [8,9], and
repetition of this immune response through training is
thought to be involved in muscle adaptation [10]. How-
ever, with aging, acute responsiveness gives way to chronic
inflammation that may be detrimental to muscle. In rats,
cytokine infusion suppresses protein synthesis and induces
muscle catabolism [11]. In humans, elevated cytokines are
associated with sarcopenia and functional decline [12].
Thus, systemic differences in immune parameters (for ex-
ample, response to vaccine, t-cell phenotype, or cytokine
levels) between older adults may reflect the individual
ability to maintain or improve muscle health despite
aging.
Specific cells of the immune system, that is, macro-
phages, appear to play an important role in muscle
hypertrophy [13]. Macrophages are thought to transition
between three functional phases in response to unaccus-
tomed exercise [14]. Phase 1 is an inflammatory response
mediated by systemic and local cytokines, such as IL1β
and TNFα, which initiate muscle repair. Macrophages,
termed M1 macrophages, produce these pro-inflammatory
cytokines and chemokines to recruit additional macro-
phages to remove cellular debris from damaged myofibers
[15]. After this initial cleanup, M2 macrophages function
in Phase 2, which includes the downregulation of inflam-
mation by anti-inflammatory cytokines, such as IL-1RA
and IL10, so that secondary damage does not occur. This
allows muscle tissue to become conducive to growth [16].
In the regenerative Phase 3, macrophage arginine metabol-
ism increases and its byproducts promote cell growth [17].
Growth factors such as IGF1 are produced to further
stimulate myogenesis [18]. Satellite cells proliferate and
Figure 1 Study objectives for a randomized trial of a nutritional
supplement designed to determine if immune function
influences the ability of older adults to improve muscle mass,
strength, function, and cellular adaptation to resistance
exercise training.
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fuse with existing fibers so that the added myonuclei can
support an increase in fiber size [19]. However, muscle in-
jury is not necessary for macrophage stimulation [20].
Thus, in the absence of damage, or as muscle adapts to
training, macrophages may be predominantly dedicated to
producing growth factors required for muscle mainten-
ance or hypertrophy.
Evidence from animal and human studies suggests that
the immune system and macrophages influence muscle
mass and strength during health and aging. In animals,
experimental reduction of muscle macrophage content
decreases the ability of muscle to hypertrophy and re-
cover from atrophy [21-23]. The effects were related to
decreased macrophage provision of the growth factor
IGF1 and decreased satellite cell differentiation, myo-
nuclear addition, and muscle fiber growth [21,23]. In
humans, muscle mass and strength gain are also associ-
ated with increases in muscle satellite cells, fiber nuclei,
and fiber size [24]; and these adaptations to exercise are
diminished in older adults [25]. Inflammation may have
contributed to those findings. In a training study of older
adults, individuals consuming anti-inflammatory drugs
gained significantly more muscle mass and strength than
those consuming placebo [26]. Our studies also indicate
that immune function influences the response to exer-
cise. The muscle cross-sectional area and strength
gained by older adults from resistance training showed a
strong positive correlation with muscle expression of
specific pro- and anti-inflammatory cytokines and
growth factors including IGF1 [4]. Muscle macrophage
content pre-training in those older adults was also
strongly correlated with pretraining growth factor levels
(R = 0.96, P <0.001) and post-training strength gain (R =
0.99, P <0.001) (Figure 2). These results suggest that
macrophages may be regulated by cytokines during exer-
cise and provide growth factors that promote the adap-
tation of muscle cells and fibers, which leads to mass
and strength gains. Thus, consumption of a nutritional
supplement that either dampens a negative or boosts a
positive effect of inflammation and immune function
could benefit older adults during exercise training.
Three signaling pathways may be involved in the regu-
lation of macrophage function, production of cytokines
and growth factors and their effects on muscle cells. M1
macrophages are regulated primarily by NFkB in re-
sponse to systemic pro-inflammatory cytokines, such as
TNFα and IL1β [27]. M1 macrophages then may be re-
sponsible for production of cytokines, which block
FOXO phosphorylation and lead to increased transcrip-
tion of the ubiquitin ligases, MuRF and MAFbx, which
control protein degradation and can lead to muscle atro-
phy [28]. Macrophage conversion to M2 function is
driven by and results in production of anti-inflammatory
cytokines, such as IL10 and CCL18, through the
activation of STAT3 [27]. These macrophages strongly
support tissue growth, as was originally characterized
due to the poor prognosis associated with their presence
in tumors. M2 macrophages may be a source of IGF1,
which promotes muscle health by blocking the FOXO
pathway and stimulating the PI3K and MAPK signaling
cascades. Activation or blockage of factors within these
pathways results in obvious effects on muscle. For ex-
ample, constitutive AKT signaling results in muscle
growth; whereas deletion of the S6K results in muscle
atrophy [29]. Examination of these pathways in human
muscle is limited to date, and further investigation is
warranted. A model for how these signaling pathways,
macrophage function, and cytokines and growth factors
hypothetically integrate to control muscle health (that is,
adaptation and performance) in the context of aging, nu-
tritional supplementation, and exercise is presented in
Figure 3.
A nutritional supplement that affects immune function
may improve the ability for older adults to reap and re-
tain the benefits of resistance training. The supplement
ingredients (Arg, Gln, and HMB) are used for nutritional
support during conditions associated with muscle wasting
or requiring tissue regeneration [5]. These ingredients
have shown success in slowing cachexia and increasing
fat-free body mass in both cancer and AIDS patients
[30,31]. The ingredients also increased fat-free mass,
strength, and muscle function after 12 weeks of consump-
tion by elderly women. They are also commonly used to
increase muscle mass and strength in combination with
resistance exercise for sports performance [5,32,33]. Des-
pite this success, little is known about the mechanism of
action. HMB may work by altering protein synthesis, but
it also enhances humoral immune function at least in ani-
mals [34-36]. Glutamine and arginine are considered
immuno-nutrients. They affect immune cells including
lymphocytes, T-cells, and macrophages by altering cell
phenotype, proliferation, and production of pro- and anti-
inflammatory cytokines [37-40]. Thus, the supplement or
its ingredients are used to support muscle health in the
extreme conditions of cachexia and sports performance,
and numerous effects on immune function have been
identified. For these reasons, conduct of a randomized
controlled trial of this particular supplement offers an op-
portunity for a mechanistic investigation of the relation-
ship between immune function and muscle adaptation to
exercise in older adults.
Study objectives
The objectives of this trial are as follows:
1. Determine the effects of nutritional supplement
consumption by older adults on the humoral
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response to vaccination and specific cellular immune
responses to an acute resistance exercise stimulus.
2. Determine if nutritional supplement consumption
affects the adaptive responses to resistance exercise
training at the whole body or cellular level.
3. Determine if nutritional supplement consumption
affects the retention of benefits of exercise during
post-training follow-up.
Methods/design
Human subject participation
Trial summary
Subjects will participate in a randomized double-blind
placebo-controlled trial of a nutritional supplement
(Figure 4). Individual participation will optimally last
47 weeks. This time will include periods for
introduction to exercise and testing of muscle function
(2 weeks), supplementation prior to training (2 weeks),
supplementation plus supervised resistance training
(12 weeks), and supplementation during post-training
follow-up (that is, detraining, 26 weeks). Subjects will
undergo five muscle biopsies and nine blood draws
total. The effects of the supplement or placebo on partici-
pant responses to a single bout of exercise, vaccination
(tetanus, diphtheria, and pertussis (TDAP)), exercise train-
ing, and detraining will be measured. The study outcomes
are listed in Table 1. Participation will require approxi-
mately 55 study visits. Subjects will be compensated for
their time via gift cards redeemable at a local grocery store
in the amount of $20 per visit plus bonuses of $100 for
completing the resistance training and $300 for complet-
ing the entire study. The study has been approved as
Figure 2 Relationships between pretraining muscle molecular and cellular measures and percent strength gain after 12 weeks of
high-intensity progressive resistance training of the thigh muscles for older adults (N = 7, Age 69 ± 6 yrs). (A). Pearson correlation
between the number of macrophages and IGF1 mRNA. The number of macrophages staining positive for CD163 by immunohistochemistry
were counted per myofiber. IGF1 mRNA was measured using quantitative real-time reverse transcriptase polymerase chain reaction. (B). Pearson correlation
between the number of muscle macrophages and strength gain for knee extension. One outlier was excluded from these analyses due to having
macrophage levels that were fourfold higher than the group average.
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required by all entities of the Central Arkansas Veterans
Healthcare System (CAVHS) including the Research and
Development Committee, CAVHS Institutional Review
Board (IRB protocol 608119), Subcommittee for Research
Safety, Privacy and Information Security Officers, and
Public Affairs Office. The study is being conducted in the
Geriatrics Research, Education and Clinical Center of a
Veterans Affairs Medical Center.
Recruitment and enrollment
Veterans (age 60 to 80 yrs, N = 50) of the United States
military are being recruited from the local community
and enrolled by study staff to participate in the 4-year
study. The county of the study site and the surrounding
counties contain approximately 36,000 veterans who
meet the age requirements for the study. An estimated
92% are white, 6% are black, and 3% are female [41].
Ethnic and racial groups are expected to enroll at least
in proportion to their representation in the community.
Vulnerable populations will not be targeted. Recruitment
will utilize flyers posted in the VA hospital, clinician refer-
ral, and newspaper advertising. Recruits will be pre-
screened by phone interview and review of their electronic
medical record. Recruit permission and the necessary
waivers of HIPAA and written consent will be used for
this process. Individuals appearing eligible will provide
written consent at their first research visit. Subjects will
undergo a medical history and physical exam performed
by the study physician, including electrocardiogram dur-
ing resistance exercise. The physician will determine eligi-
bility based on the American College of Sports Medicine
guidelines for resistance exercise and the exclusion criteria
related to specific study procedures (Table 2) [42].
Randomization
Subjects will be randomized to parallel groups to con-
sume either nutritional supplement or placebo. The hos-
pital research pharmacist will perform the double-blind
randomization using variable block sizes with an
Figure 4 Timeline for individual subject participation. Each individual will participate in the study for approximately one year. Participation
will include consumption of a nutritional supplement or placebo twice daily for 42 weeks. During this time, subjects will also complete 12 weeks
of resistance training followed by 26 weeks of post-training follow-up (that is, a detraining period). The particular procedures and assessments
involved during each week of participation are listed. X/X denotes assessment of response to a single bout of exercise by collecting specimens
before and after exercise for blood (1 hour) and muscle (72 hours). The scheduling timeline is approximate and can be extended based on
the scheduling needs of the subjects and study staff.
Figure 3 Proposed model for how a nutritional supplement
promotes a shift in immune system function in older adults
from a pro-inflammatory state (both at rest and in response to
a bout of exercise) towards a state in which inflammation is
dampened so that muscle growth in response to exercise training
is supported. The supplement is proposed to augment muscle
adaptation and performance gains from resistance training by
altering macrophage and muscle cell phenotype through specific
cytokines, growth factors, and signaling pathways.
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allocation ratio of 1:1. The randomization scheme was
generated using the website http://www.randomization.
com. Assignments will be unknown to investigators and
subjects. The study will enroll 50 subjects total to allow
for up to 20% dropout to have at least 40 complete the
protocol. The hospital pharmacy will dispense supple-
ment and placebo in blinded packaging. The protocol
appointed a study monitor (specific un-blinded member
of the study team) to review and be involved in phar-
macy and subject compliance but not involved in subject
assessments or specimen analysis.
Supplementation
The ingredients of the nutritional supplement (Muscle
Armor, Abbott Laboratories, Columbus, OH) and pla-
cebo (Kool-Aid, Kraft Foods Group, Northfield, IL) are
listed in Table 3. Subjects in the supplement group will
consume orange-flavored supplement according to the
manufacturer’s directions: one serving (approximately
30 g), twice daily (optimally morning and evening),
mixed with 12 oz of water. Subjects in the placebo group
will similarly consume approximately 13 g of orange-
flavored placebo mixed with 12 ounces of water twice
daily. Supplementation will begin the day of the second
muscle biopsy and continue for the remainder of the
participant’s study involvement. Compliance will be
monitored by subject self-report on a dosing calendar as
well as by the study monitor calculating the weight of
product consumed. Products will be dispensed in
blinded sealed canisters containing 14 doses. Subjects
will return any unused product. The monitor will review
dosing and consumption for compliance with the subject
approximately every 4 weeks or more often as needed.
Subject dietary data will not be collected but to be in-
volved subjects must agree to maintain their normal diet
during participation.
Vaccination
The TDAP vaccine (Adacel, Sanofi Pasteur, Swiftwater,
PA) will be administered by a study physician or nurse
to each subject after 2 weeks of supplementation (day of
third muscle biopsy) (Figure 4). Blood will be collected
at baseline and 1 and 2-weeks post-immunization to de-
termine the effects of the supplement on the humoral
response. Two post-vaccination time-points were chosen
in case the response is delayed in older adults relative to
the response in younger adults [43]. If needed to accom-
modate scheduling, the supplementation period may be
extended and the two post-vaccination blood draws may
be delayed by one day if necessary.
Resistance exercise
The study will use a resistance exercise routine that we
have previously used to elicit cellular and molecular re-
sponses in muscle associated with immune function and
to improve muscle mass and strength of the thigh for
older adults [4,9,14,44]. The resistance exercise program
will use three exercises to strengthen the thigh muscles,
including bilateral knee extension, knee curl, and leg
press. Exercises will be completed on air-driven exercise
equipment (Keiser, Fresno, CA) in a seated position and
always supervised by a study team member. Strength
testing will utilize the 1-repetition maximum (1RM) test
[45]. A brief warm-up period will include 10 minutes of
mild aerobic activity on a cycle ergometer. For each ex-
ercise, approximately six repetitions of lifting warm up
will be completed at a ‘somewhat heavy’ (that is, ap-
proximately 65% 1RM) load. The load will then be grad-
ually (approximately 5 to 10%) increased such that the
maximum capability for lifting is reached in approxi-
mately ten total repetitions. Subjects will rest 60 seconds
between repetitions after the warm up. Subjects rest
5 minutes prior to the next test completed in the order
Table 1 Study outcomes for immune responses to various stimuli and for muscle adaptation to training
Immune function Muscle adaptation
Blood measures Whole body measures
Antibody response to TDAP vaccine1 1-Repetition maximum strength5
Pro- and anti-inflammatory T-Cell population balance2 Thigh cross-sectional area (CT scan)
Pro- and anti-inflammatory cytokine/chemokine levels2 6-minute walk and gait speed tests
Proliferation of peripheral blood mononuclear cells3 Berg Balance Scale
C-Reactive Protein5 Timed Up and Go test
Muscle tissue measures Muscle tissue measures
Change in CD163+ Macrophages2, 5 Change in satellite cell numbers
Changes in pro- and anti-inflammatory cytokines2 Change in fiber size
Growth factor levels4 Nuclear addition to muscle fibers
NFkB, PI3 Kinase, FOXO, and STAT3 signaling pathways2
1Humoral response to the tetanus, diphtheria, and pertussis (TDAP) vaccine; 2Response to an unaccustomed bout of exercise; 3In vitro stimulation assay; 4Resting
measure; 5Primary outcome measures used in power calculations while other outcomes are secondary.
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of press, curl, and extension. Subjects will complete one
introduction to the exercise session and undergo
strength testing twice during the first 2 weeks of partici-
pation. Subjects will then have at least 2 weeks of rest
prior to the unaccustomed exercise sessions. The pur-
pose of this rest period is to mitigate any possible effects
on the muscle tissue analysis.
Unaccustomed exercise sessions
Prior to exercise training, the study will measure the re-
sponse to single bouts of the training exercises before and
after two weeks of nutritional supplementation (Figure 4).
The unaccustomed exercise session will be the same as
each session completed for exercise training as described
below. The response to exercise will be measured using
both muscle and blood. The pre-exercise biopsy time
points will be prior to exercise, possibly the same day or a
different day, based on scheduling and/or the judgment of
the study physician. The post-exercise time points for col-
lection are 72 hrs for muscle and 1 hr for blood. Our stud-
ies have previously shown that 72 hrs is better than
24 hours for measuring the immune variables of interest
in muscle [9]. The 1 hr time point for blood collection is
based on other studies that have determined the effects of
exercise on systemic measures of immune function [8,46].
Exercise training sessions
The training program will have subjects perform super-
vised exercise for approximately an hour three times per
week on nonconsecutive days. The program consists of
36 exercise sessions that will optimally take 12 weeks
though the total time will likely be longer due to sched-
uling based on the needs of the subject or the study
team. The exercise load will be based on the subject
1RM. After a light cycling warm up, subjects will per-
form four sets of each exercise at loads of 60, 70, 75, and
80% of their measured capability. Strength is retested at
every sixth session to account for strength gain in main-
taining the work load. On days of testing, the strength
test replaces the first of the four exercise sets. Strength
is also tested twice prior to training, at the final training
bout, and twice during the post-training follow-up
period. Training sessions consist of three sets of ten rep-
etitions for each exercise and a fourth set completed at
voluntary failure to complete a repetition. Subjects will
rest approximately 2 minutes between each set and
Table 2 Study inclusion and exclusion criteria
Inclusion criteria
• U.S. Military Veteran • Age 60 to 80 years
• Nonsmoker of tobacco
products
• Body Mass Index of 18.5 - 29.9 kg/m2
Exclusion criteria
• Unstable angina • Uncontrolled diabetes mellitus (HbA1C > 10)
• Allergic to lidocaine • Problems walking or exercising with both
legs
• Allergic to vaccination • Metastatic cancer or undergoing
chemotherapy
• Allergic to latex or tape • Hernia that causes pain during physical
activity
• Seizure in past 3 months • Tetanus or TDAP vaccine in previous two
years
• Smokes tobacco
products
• Certain steroid or androgen use in past
3 months
• Other physician
judgment
• Cerebral aneurysm or intracranial bleed in
past year
• Systemic bacterial
infection
• Unwilling to halt new use of nutritional
supplements
• Active oral or genital
herpes
• End-stage congestive heart failure (NYHA
Stage IV)
• Bleeding or clotting
disorders
• Unstable abdominal or thoracic aortic
aneurysm (>4 cm)
• Encephalopathy in past
7 days
• Myocardial infarction or cardiac surgery in
past 3 months
• Untreated severe aortic
stenosis
• Pains, tightness, pressure in chest during
physical activity
• Renal disease requiring
dialysis
• Significantly abnormal blood tests (CBC or
PT/PTT/INR)
• Uncontrolled asthma or
allergies
• Bone fractures in the pelvis, legs, or feet in
the last 3 months
• Significant problem with
fainting
• Taking prescription anti-coagulants (that
is, heparin, warfarin, etcetera)
• Current use of appetite
stimulants
• Current treatment for mania or bipolar
disorder or taking lithium
• History of peripheral
artery disease
• Pulmonary embolism or deep venous
thrombosis in past 3 months
• Active suicidality or
suicidal ideation
• Taking lactulose, nitrates plus
hypertension medications or Viagra
• Significant problems with
chronic pain
• Uncontrolled hypertension or hypotension
(>160/100, <100 systolic)
• Unwilling to maintain
current normal diet
• Acute retinal hemorrhage or
ophthalmologic surgery in past 3 months
• Diagnosis of a significant
cognitive deficit
• Unwilling to halt concurrent use of amino
acid or protein supplements
• Guillain-Barre Syndrome
in past 3 months
• Proliferative diabetic retinopathy or severe
nonproliferative retinopathy
• Uncontrolled malignant
cardiac arrhythmia
• Participated in a weight-lifting program
targeting the thighs in last 3 months
• Liver cirrhosis or other
severe liver disease
• Currently participating in any other
research study involving an intervention
• Taking aspirin in any form and unable/unwilling to discontinue for
10 days prior to muscle biopsy
Table 2 Study inclusion and exclusion criteria (Continued)
• Taking any non-aspirin non-steroidal anti-inflammatory drug and
unable or unwilling to discontinue use for 3 days prior to the muscle
biopsy procedure
• Taking Fish Oil, Gingko, Garlic, Saw Palmetto, Turmeric, or Vitamin E
and unable or unwilling to discontinue use for 10 days prior to the
muscle biopsy procedure
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approximately 5 minutes between exercises. Exceptions
to the plan for each subject to complete 36 exercise
training sessions may be necessary on a case-by-case
basis in order to ensure that the final muscle biopsy of
the protocol, needed for assessment of muscle adapta-
tion, occurs 72 hours (3 days) after the final exercise
training session. After each exercise session or as needed
during exercise, subjects will be guided through stretch-
ing of the quadriceps, hamstrings, and other affected
muscles.
Post-training follow-up
The subjects will remain in the study after completion of
the training program for 26 additional weeks. The reten-
tion of muscle mass, strength, and function will be ex-
amined relative to continued daily consumption of
supplement or placebo (Figure 4). Subjects will be re-
quired to refrain from strength training of the thighs
(that is, weight lifting, body weight exercise, and elastic
bands) during this period. It is acceptable for subjects to
participate in other forms of exercise such as walking.
Compliance with these and study dietary requirements
will be monitored by subject query at monthly visits dur-
ing the follow-up period. These visits are also required
for dispensing of product from the pharmacy and moni-
toring of consumption compliance.
Functional assessments
Functional assessment data will be collected at four
times during the protocol: pre-training, post-training,
during post-training follow-up, and at end of the post-
training follow-up (Figure 4). Four assessments of
muscle function will be performed. The Berg Balance
Scale will be used to detect balance impairments in older
adults while the individual is static or performing vari-
ous movements [47]. The Six Minute Walk Test will be
used to measure mobility performance [48]. The subjects
will perform a supervised timed walk on a 200-foot track
at a pace without encouragement and that allows speech
without shortness of breath. The Gait Speed will be
measured as habitual walking speed [49]. The subjects
will walk at their normal preferred pace for 14 meters
though only the middle 10 meters are timed. The result
is an average of three replicates. Subjects will also
complete the Timed Up and Go test. The test is indica-
tive of balance and mobility by a measuring the time re-
quired for the subject to rise from a chair, walk 3
meters, turn around, walk back to the chair, and sit
down [49].
Muscle cross-sectional area
Muscle size will be determined by the hospital imaging
service using a CT scan of the mid-thigh of the domin-
ant leg at three time points during the protocol: pre-
training, post-training, and at end of the post-training
follow-up (Figure 4). Subjects will rest in a supine pos-
ition for 30 minutes prior being precisely positioned in
the scanner. The CT image will then be taken at the
midpoint between the inguinal fold and proximal pole of
the patella, along the femur. A blinded analysis of the
scans will be completed using Slice-O-Matic software
(Montreal, Canada) to discern between Hounsfield units
for bone (+1000), fat (-190 to -30), and normal (40 to
100) and low (0 to 30) density muscle.
Muscle biopsy and blood draws
Subjects will undergo five muscle biopsies and nine
blood draws in order to assess the effects of nutritional
supplementation on immune function and cellular mea-
sures of muscle adaptation (Figure 4 and Table 1), though
blood will also be used to assess subject eligibility and
safety. Muscle tissue will be obtained from each subject by
needle biopsy of the vastus lateralis (outer thigh) by a
study physician. The procedure is performed after local
anesthetic (bicarbonate buffered lidocaine) is used to
numb the site. A small incision will be made in the skin
Table 3 Comparison of nutrient information between nutritional supplement and placebo mixed in 12 oz water
Supplement Per serving Placebo Per serving
AMINO ACIDS AMINO ACIDS
L-ARGININE 7 g L-ARGININE 0 g
L-GLUTAMINE 7 g L-GLUTAMINE 0 g
TAURINE 3 g TAURINE 0 g
CARBOHYDRATE 10 g CARBOHYDRATE 12 g
SUGARS 5 g SUGARS 12 g
MINERALS MINERALS
CALCIUM 200 mg CALCIUM 0 mg
Calcium β-hydroxy-β-methylbutyrate 1.5 g Calcium β-hydroxy-β-methylbutyrate 0 g
VITAMIN C 0 mg VITAMIN C 7 mg
ENERGY 110 kcal ENERGY 46 kcal
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and a Bergstrom needle will be inserted briefly into the
muscle so that suction and closing of the needle can be
used to obtain 100 to 200 mg of muscle. Direct pressure
will be applied to stop the bleeding and the wound will be
closed and covered with a pressure bandage. Pre-exercise
biopsies will be taken from the dominant leg while post-
exercise biopsies will be taken from the nondominant leg.
Blood draws will be performed by a study phlebotomist or
unit nurse. The blood will most likely be drawn from the
antecubital vein (≤60 ml or 2 oz). Fasting is not a
requirement.
Data safety and monitoring plan
The following plan has been adapted from ‘Guidelines
for Data and Safety Monitoring for Clinical Trials Not
Requiring Traditional Data Monitoring Committees’
[50]. The study has eligibility criteria that have been pre-
cisely defined to ensure enrollment of subjects who pos-
sess an appropriate risk/benefit ratio (Table 2). Safety
monitoring will be performed from enrollment until at
least 30 days postparticipation for each subject. Monitor-
ing occurs by query of the patient medical record and
subject self-report or exam at each research visit, as well
as during telephone contacts. Expected adverse events
are listed in the informed consent document and will be
monitored for, as will serious adverse events and unex-
pected adverse events possibly related to participation.
Appropriate action relative to the severity of the event
will be taken by the study team immediately when an
event is identified. This may range from documentation
by the coordinator (for example, mild muscle soreness)
to safety examination by the study physician (for ex-
ample, elevated blood pressure after exercise). The study
procedures (for example, exercise or supplementation)
will be halted at any time a safety concern is identified.
Halted procedures will not resume until the concern has
been alleviated. If concerns cannot be alleviated, then
the study physicians may rule to withdraw the subject,
modify the protocol, suspend enrollment, or halt the
study. This is a relatively small single-site study, which
allows decisions to be made in real-time as problems
occur, rather than after aggregate data collection and in-
terim analysis. Adverse events will be reported in com-
pliance with IRB policy.
Research laboratory analyses
Blood measures
Plasma and monocytes derived from blood draws at the
time points listed in the Statistical Plan section will be
used to measure four types of variables related to im-
mune function (Table 1):
1. The responses to vaccination against tetanus,
diphtheria, and pertussis will be assessed using
enzyme-linked immunosorbent assays to measure
antibody titers to the vaccine antigens (IBL International,
Toronto, Ontario).
2. The study will determine if 2 weeks of
supplementation increases the ratio of naïve helper
(CD4+) to cytotoxic (CD8+) T-cells at rest or in
response to acute exercise. The effects on other T-
reg (T-regulatory) or Th17 T-cell subsets may also
be examined. T-cell subset analysis will be carried
out by flow cytometry using fluorochrome-linked
antibodies specific to each marker (BD Biosciences,
San Jose, CA).
3. The levels of pro- and anti-inflammatory cytokines
and chemokines will be measured in plasma. Examples
include Th1 cytokines (IFN-γ, TNF-α, IL-2, and IL-17)
and Th2 cytokines (IL-10 and IL-4). Cytokines and
chemokines will be measured using the multiplex
Luminex array system (Bio-Rad, Hercules, CA, USA)
and confirmed using high sensitivity enzyme-linked
immunosorbent assays (R & D Systems, Minneapolis,
MN, USA). C-reactive protein levels will also be
measured by the hospital clinical laboratory.
4. The study will also evaluate immune cell
proliferative ability for each individual. The study
will determine if 2 weeks of supplementation
increases the in vitro proliferative capacity of
peripheral blood mononuclear cells at either baseline
or after acute resistance exercise. Proliferation will
be measured by flow cytometry based on uptake of a
fluorescent dye (carboxyfluorescein succinimidyl
ester) after treatment with phorbol ester and
ionomysin, a calcium ionophore [51].
Muscle measures
Muscle tissue collected by biopsy at the time points
listed in Figure 4 will be used to measure four types of
variables related to immune function and muscle adapta-
tion (Table 1):
1. The study will determine if 2 weeks of supplementation
increases the number of macrophages present in
muscle at baseline or in response to acute resistance
exercise. Macrophages will be counted in muscle
cross-section by immunohistochemistry using
antibodies to detect the CD163 marker (Cell
Sciences, Canton, MA). Additional markers
(CD68 and CD206) will be used to confirm the
specificity of the CD163 marker to macrophages.
2. Muscle levels of cytokines and growth factors will be
assessed. The study will determine if 2 weeks of
supplementation decreases baseline cytokine levels
and increases the response to acute exercise. The
study will also determine if supplementation
increases growth factor levels at baseline and in
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response to acute exercise. IL1β, IL10, and IGF1 are
of primary interest, though other cytokines and
growth and remodeling factors including MuRF and
MAFbx will also be measured. Gene expression will
be measured at the mRNA level using total RNA
extracted from whole muscle by quantitative
real-time PCR using SYBR green chemistry and
standard curves [4,9,44].
3. The study will evaluate signaling proteins that may
be involved in the regulation of muscle phenotype.
The study will determine if 2 weeks of
supplementation decreases NFkB signaling and
increases PI3K signaling at baseline and in response
to exercise. NFkB activity will be assessed by
electrophoresis mobility shift assays to detect muscle
nuclear protein binding to the NFkB DNA site [52].
PI3K activity will be assessed by Western Blot based
phosphorylation assays (Millipore, Billerica, MA).
Other signaling proteins of interest include FOXO1,
STAT3, AKT, S6K, and ERK1 and 2. Matched
antibody pairs are available to measure the ratio of
these phosphorylated to un-phosphorylated proteins
by Western Blot (Cell Signaling Technology, Boston,
MA).
4. Muscle adaptation to training will be measured at
the cellular levels by analyses of satellite cells and
myofibers. The study will determine if
supplementation during resistance training increases
the number of satellite cells and myonuclei per
myofiber in muscle compared to training without
supplementation. Satellite cells (Pax7+, CD56+,
DAPI+) and myonuclei (Dystrophin plus DAPI
staining) will be counted using established staining
and immunohistochemistry methods [24]. Changes
in myofiber size in response to training and
supplementation will also be measured
microscopically, as the average percent increase in
fiber cross-sectional area from baseline to post-training.
Statistical plan
Study power and hypothesis
The sample size (N = 50) will allow for 20% drop-out,
while providing 80% power for the study objectives to
detect mean differences between groups of 0.8 to 0.85
SD units at a 5% level of significance. Power calculations
were based on using a one-sided t-test to compare inde-
pendent groups using data from our work and others
[14,26,53] though non-parametric tests or transforma-
tions will be used as necessary for data containing out-
liers. There is no formal plan to adjust for multiple
comparisons. However, multiple correlation analysis will
be used to determine the correlation between endpoints,
which will aid in assessing the degree of inflation in the
overall Type I error rate. This analysis will allow testing
of the overall hypothesis that measures of immune func-
tion (Objective 1) will be positively correlated with adap-
tations to exercise (Objective 2) and retention of muscle
strength, mass, and function after exercise training is
halted (Objective 3). The hypotheses are stated for each
objective based on the following lettered time points for
comparison:
BASELINE MEASURE TIME POINTS (WEEKS 1 to 5)
A. Blood draw at study enrollment for measuring
pre-vaccination antibody titers
B. Assessment of muscle strength, mass, and function
at baseline
C. Blood draw prior to acute exercise at baseline
D. Muscle biopsy prior to acute exercise at baseline
E. Blood draw 1 hr after acute exercise at baseline
F. Muscle biopsy 72 hrs after acute exercise at baseline
POST-SUPPLEMENT PRE-TRAINING MEASURE TIME
POINTS (WEEK 8)
G. Blood draw prior to acute exercise after weeks of
supplementation
H. Muscle biopsy prior to acute exercise after 2 weeks
of supplementation
I. Blood draw 1 hr after acute exercise after 2 weeks of
supplementation
J. Muscle biopsy 72 hrs after acute exercise after 2 weeks
of supplementation
MEASURE TIME POINTS DURING TRAINING PERIOD
(WEEKS 9 to 20)
K. Blood draws at weeks 1 and 2 post-vaccination for
measuring antibody response
POST-TRAINING MEASURE TIME POINTS (WEEK
21)
L. Assessment of muscle strength, mass, and function
after completion of training
M. Muscle biopsy 72 hrs after final exercise bout of
training
MEASURES DURING POST-TRAINING FOLLOW-UP
(WEEKS 22 to 47)
N. Assessments of strength, mass, and function after 17
and 26 weeks of detraining
Objective 1 power and hypotheses
The study will determine if supplement consumption for
2 weeks improves baseline measures of immune function
or the immune responses to vaccination or acute
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exercise. The representative measures chosen to calcu-
late power are change in muscle macrophage content
after acute exercise [14] and change in CRP levels after
two weeks of supplementation in a randomized double-
blind pilot study involving older adults and the current
study inclusion and exclusion criteria (unpublished
data). Przybyla et al. detected a 29% increase in CD163+
macrophages in young subjects after exercise but no
change in older subjects [14]. Power for this aim is cal-
culated to detect at least a 29% greater increase in mac-
rophages in the supplement than the placebo group.
Przybyla et al. used a nonparametric test to lessen the
effects of outliers. To be more conservative here, the cal-
culations dropped the most extreme high and low data
values before estimating effect sizes. With that approach,
the 29% increase corresponds to an effect size of 0.8 SD
units (mean/SD = 0.128/0.159). Similar results were
found using data suggesting that CRP levels decreases in
older adults after supplementation. The effect size for
change in CRP is 0.85 SD units (mean/SD = 0.665/0.780
for log-transformed data). Having 20 subjects per group
will provide 80% power to detect a mean shift of 0.8 to
0.85 SD units at a significance level of 5% for the follow-
ing Objective 1 hypotheses:
1. The response to vaccination will be greater in the
supplement than the placebo group. The change
between times K and A will be compared between
groups.
2. The resting ratio of CD4+ to CD8+ t-cells will
increase in the supplement but not in the placebo
group. The change between times G and C will be
compared between groups.
3. The change in t-cell subsets after acute exercise will
be greater in the supplement than the placebo
group. The change between times I and G will be
compared to the change between times E and C for
both groups.
4. Resting cytokine levels will decrease in the
supplement but not in the placebo group. Change
will be compared between groups for blood (times G
and C) and muscle (times H and D). Similar results
are predicted for the MuRF and MAFbx atrophy-related
transcripts.
5. The increase in cytokine levels after acute exercise
will be greater in the placebo group than the
supplement group. For both groups, change between
times I and G will be compared to the change
between E and C for blood, and for muscle the
change between times J and H will be compared to
the change between times F and D.
6. The proliferative capacity of peripheral blood
mononuclear cells will be greater in the supplement
than the placebo group. The change between times
G and C will be compared between groups. The
change between times I and E will also be compared
between groups.
7. The resting number of muscle CD163+
macrophages will increase in the supplement but not
in the placebo group. The change between times H
and D will be compared between groups.
8. The number of muscle CD163+ macrophages will
increase after acute exercise in the supplement but
not in the placebo group. The change between times
J and H will be compared to change between times
F and D for both groups.
9. Resting NFkB activity will decrease, and PI3K
activity will increase in the supplement group but
not in the placebo group. The change between time
points H and D will be compared between groups.
10. In response to acute exercise, NFkB activity will be
lower, and PI3K activity will be greater in the
supplement group than in the placebo group. The
change between times J and H will be compared to
change between times F and D for both groups.
Responses similar to NFkB are predicted for
FOXO1, and responses similar to PI3K are expected
for STAT3, AKT, P38 MAPK, and ERK 1 and 2.
Objective 2 power and hypotheses
The study will determine whether supplement consump-
tion increases muscle adaptation to 12 weeks of resist-
ance training. The representative response measure for
this objective is post-training percent increase in muscle
strength. In a similar study, Trappe et al. sought to im-
prove strength gain by resistance training plus drug
treatment [26]. The drug treatment group gained signifi-
cantly more strength by 25.1% than the group receiving
placebo (26.4% versus 21.1%, P <0.05). Our previous
findings indicate that older subjects completing a 12-
week training program but not taking supplements will
experience an average strength gain of 25 ± 8% [4]. If
treatment with the proposed supplement improves
strength similarly to the Trappe drug treatment, subjects
in the supplement group will improve strength by an
average of 31% (that is, 25.1% greater than those of the
placebo group). This translates to an approximate effect
size of 0.8 SD units (0.25*0.251/0.08) if variances are
pooled for the groups compared. With 20 subjects per
group, there will be 80% power to detect a mean shift of
0.8 SD units using a significance level of 5% for the Ob-
jective 2 hypotheses:
1. The amount of strength gained from resistance
training will be greater in the supplement than the
placebo group. The change between times L and B
will be compared between groups.
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2. The amount of muscle size gained from resistance
training will be greater in the supplement than the
placebo group. The change between times L and B
will be compared between groups.
3. The increase in muscle function after resistance
training will be greater in the supplement than the
placebo group. The change between times L and B
will be compared between groups.
4. The increase in muscle satellite cells after resistance
training will be greater in the supplement than the
placebo group. The change between times M and D
will be compared between groups.
5. The increase in muscle myonuclei after resistance
training will be greater in the supplement than the
placebo group. The change between times M and D
will be compared between groups.
6. The increase in muscle fiber size after resistance
training will be greater in the supplement group
than the placebo group. The change between times
M and D will be compared between groups.
Objective 3 power and hypotheses
The study will determine if supplement consumption in-
creases the retention of exercise-derived benefits post-
training during 26 weeks of long-term follow-up. The
representative response measure for this objective is the
strength gain retained during long-term follow-up after
exercise training is completed. Lemmer et al. observed
an average gain in muscle strength of 27% (P <0.01) in
older men after strength training, which is similar to the
25% gain in our study [53]. However, at 31 weeks of
post-training follow-up, strength had decreased to be
about 9% above the pretraining levels. Assuming the
same level of variation among our subjects in retention
of strength gain as the observed 8% SD for our study,
then a 0.8 SD effect size would be about 6.4% (0.8*0.08),
translating to our supplement group retaining strength
of 12.4% above pretraining levels. With 20 subjects per
group, there will be 80% power to detect a mean shift of
0.8 SD units using a significance level of 5%. If the SD
for retention of strength is smaller than 8%, then the
study will have higher power to detect the same differ-
ence or equal power to detect smaller differences for the
following Objective 3 hypotheses:
1. The change in strength during the detraining period
will be smaller in the supplement than the placebo
group. The change between times N and L will be
compared between groups.
2. The change in muscle size during the detraining
period will be smaller in the supplement than the
placebo group. The change between times N and L
will be compared between groups.
3. The change in muscle function will be smaller in the
supplement than the placebo group. The change
between times N and L will be compared between
groups.
Discussion
The study seeks to determine if a nutritional interven-
tion can target the immune system and complement re-
sistance exercise in helping older adults improve and
maintain muscle health. The study is unique in that
while exercise is known to have clear effects on immune
function [54], little is known about the effects of im-
mune function on individual ability to benefit from exer-
cise. This is because few studies have altered immune
function and determined the effects on training out-
comes. The proposed study will attempt to do this using
a nutritional supplement known to support muscle
health. The supplement’s mechanism of action is un-
known, but the ingredients alter measures of immune
function that will be measured by the study. The study
will also examine detraining, an important issue for
older adults that is often omitted from training studies
[55]. The study will evaluate a nutritional intervention as
a complement to exercise for improving muscle health
during aging, but the results may only be immediately
applicable to relatively healthy older white males due to
the stringency of the exclusion criteria and the racial
and gender makeup for 60 to 80 year old U.S. veterans.
Thus, follow-up studies in other populations, particularly
those in need of muscle rehabilitation, may be warranted
and necessary. The study also has the potential to ad-
vance our understanding of the mechanisms of muscle
gain and loss in older adults. Granted, the proposed
model (Figure 3) is an ambitious investigation and an
oversimplification of the cellular and molecular determi-
nants of muscle phenotype. To overcome this limitation,
the study has been approved to allow flexibility in the
specific methods and measures of immune function in
muscle or blood for practical or scientific reasons and
not be considered a protocol deviation so long as the
measure 1) addresses a molecular or cellular trait poten-
tially impacted by aging and muscle health or the im-
provements of muscle health by supplementation or
exercise; 2) is not genetic testing; and 3) the results will
not be communicated back to the subjects or used to in-
fluence their medical care in any way.
In conclusion, a randomized controlled trial of nutri-
tional supplement use by older adults during resistance
exercise training and post-training follow-up will be con-
ducted. The individual benefits and potential scientific
advancement far outweigh the risks of participation.
High intensity training can be safely performed with
benefit by older adults including nursing home residents
over 90 years of age [56]. However, the magnitude of the
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response to training varies significantly even between
young and healthy individuals [3]. Considering this inter-
individual variation, complementary interventions such
as nutritional supplementation and a better understand-
ing of the role of immune function in muscle adaptation
to training and detraining may be valuable in optimizing
preventative and rehabilitative exercise programs for
older adults.
Thus, the importance of the scientific knowledge to be
gained is also high. The risks of exercise, the supplement
ingredients, and percutaneous muscle biopsy are rela-
tively low compared to the possibility that targeting the
immune system may be the advantage needed for certain
older adults to successfully maintain or restore the mass,
strength, and function that is necessary for personal in-
dependence, health, and quality of life [57-59].
Trial status
The study has been active and open for recruitment
since 5 August 2014.
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